Share this Article
Singapore Med J 2013; 54(12): 673-677; http://dx.doi.org/10.11622/smedj.2013240
Re-emergence of chronic obstructive pulmonary disease: it is time to think COPDifferently
Tee KH
Correspondence: Adj Asst Prof Augustine Tee, augustine_tee@cgh.com.sg
ABSTRACT
Knowledge of chronic obstructive pulmonary disease (COPD) as a common, preventable and treatable condition has advanced in the last two decades, as evidenced by the increase in scientific literature. Tobacco smoking still remains a predominant risk factor for COPD. Thus smoking cessation management should be obligatory in every case. Although spirometry is integral to the diagnosis of COPD, one should also be aware of its limitations. COPD is a chronic disease associated with comorbidities that define its extrapulmonary manifestations. Systemic inflammation provides the biological link, while exacerbations play a prominent role in the current approach to disease evaluation. This paper reviews the latest Global Initiative for Chronic Obstructive Pulmonary Disease revision, focusing on the paradigm shift in assessment that would directly influence therapeutic decisions. Also discussed are the newer drugs and combinations of existing inhaler therapies that now present clinicians with more options, as well as bronchoscopic interventions that may perhaps offer a lower-morbidity alternative than surgical lung volume reduction. Finally, this review highlights how integrated care models can bridge the gap between components and complete a comprehensive sphere of COPD care.
Keywords: chronic airflow obstruction, chronic bronchitis, chronic obstructive pulmonary disease, COPD pulmonary emphysema
Singapore Med J 2013; 54(12): 673-677; http://dx.doi.org/10.11622/smedj.2013240
REFERENCES
| 1. Global Initiative for Chronic Obstructive Lung Disease. GOLD – the Global Initiative for Chronic Obstructive Lung Disease. Available at: www.goldcopd.org. Accessed November 29, 2013. | ||||
| 2. Petty TL. The history of COPD. Int J Chron Obstruct Pulmon Dis 2006; 1:3-14. http://dx.doi.org/10.2147/copd.2006.1.1.3 | ||||
| 3. Fishman AP. One hundred years of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 941-8. | ||||
| 4. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance–United States, 1971–2000. MMWR Surveill Summ 2002; 51:1-16. | ||||
| 5. Takahashi T, Ichinose M, Inoue H, et al. Underdiagnosis and undertreatment of COPD in primary care settings. Respirology 2003; 8:504-8. http://dx.doi.org/10.1046/j.1440-1843.2003.00501.x | ||||
| 6. Criner GJ, Cordova F, Sternberg AL, et al. The national emphysema treatment trial (NETT): Part I: Lessons learned about emphysema. Am J Respir Crit Care Med 2011; 184:763-70. http://dx.doi.org/10.1164/rccm.201103-0454CI | ||||
| 7. Ministry of Health Singapore, Statistics, Singapore Health Facts [online]. Available at: http://www.moh.gov.sg/content/moh_web/home/statistics/Health_Facts_Singa.... Accessed July 26, 2013. | ||||
| 8. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1:1645-8. http://dx.doi.org/10.1136/bmj.1.6077.1645 | ||||
| 9. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009; 374:733-43. http://dx.doi.org/10.1016/S0140-6736(09)61303-9 | ||||
| 10. Zeng G, Sun B, Zhong N. Non-smoking-related chronic obstructive pulmonary disease: a neglected entity? Respirology 2012; 17:908-12. http://dx.doi.org/10.1111/j.1440-1843.2012.02152.x | ||||
| 11. Raupach T, Merker J, Hasenfuss G, Andreas S, Pipe A. Knowledge gaps about smoking cessation in hospitalized patients and their doctors. Eur J Cardiovasc Prev Rehabil 2011; 18:334-41. http://dx.doi.org/10.1177/1741826710389370 | ||||
| 12. HPB-MOH Clinical Practice Guidelines 1/2013 Treating Tobacco Use and Dependence [online]. Available at: http://www.hpb.gov.sg/HOPPortal/publication-article/HPB049610. Accessed July 26, 2013. | ||||
| 13. Vestbo J, Hurd SS, Agust? AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD Executive Summary. Am J Respir Crit Care Med 2013; 187:347-65. http://dx.doi.org/10.1164/rccm.201204-0596PP | ||||
| 14. International COPD coalition. Worldwide Survey on Early COPD Diagnosis [online]. Available at: http://www.internationalcopd.org/WCDMaterials/Worldwide_Survey_on_Early_... is.aspx. Accessed July 26, 2013. | ||||
| 15. Rennard S, Thomashow B, Crapo J, et al. Introducing the COPD Foundation Guide for Diagnosis and Management of COPD, recommendations of the COPD Foundation. COPD 2013; 10:378-89. http://dx.doi.org/10.3109/15412555.2013.801309 | ||||
| 16. Wan ES, Hokanson JE, Murphy JR, et al. Clinical and radiographic predictors of GOLDunclassified smokers in the COPDgene study. Am J Respir Crit Care Med 2011; 184:57-63. http://dx.doi.org/10.1164/rccm.201101-0021OC | ||||
| 17. Mair G, Miller JJ, McAllister D, et al. Computed tomographic emphysema distribution: relationship to clinical features in a cohort of smokers. Eur Respir J 2009; 33:536-42. http://dx.doi.org/10.1183/09031936.00111808 | ||||
| 18. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186:155-61. http://dx.doi.org/10.1164/rccm.201201-0034OC | ||||
| 19. Luppi F, Franco F, Beghé B, Fabbri LM. Treatment of chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc 2008; 5:848-56. http://dx.doi.org/10.1513/pats.200809-101TH | ||||
| 20. Balasubramanian VP, Varkey B. Chronic obstructive pulmonary disease: effects beyond the lungs. Curr Opin Pulm Med 2006; 12:106-12. http://dx.doi.org/10.1097/01.mcp.0000208449.73101.ac | ||||
| 21. Sethi S, Mahler DA, Marcus P, et al. Inflammation in COPD: implications for management. Am J Med 2012; 125:1162-70. http://dx.doi.org/10.1016/j.amjmed.2012.06.024 | ||||
| 22. MacDonald M, Beasley RW, Irving L, Bardin PG. A hypothesis to phenotype COPD exacerbations by aetiology. Respirology 2011; 16:264-8. http://dx.doi.org/10.1111/j.1440-1843.2010.01908.x | ||||
| 23. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007; 29:1224-38. http://dx.doi.org/10.1183/09031936.00109906 | ||||
| 24. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:1128-38. http://dx.doi.org/10.1056/NEJMoa0909883 | ||||
| 25. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124:459 - 67. http://dx.doi.org/10.1378/chest.124.2.459 | ||||
| 26. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med 2013; 187:347-65. http://dx.doi.org/10.1164/rccm.201204-0596PP | ||||
| 27. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34:648-54. http://dx.doi.org/10.1183/09031936.00102509 | ||||
| 28. Tashkin DP, Celli B, Senn S, et al. A 4-Year Trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543-54. http://dx.doi.org/10.1056/NEJMoa0805800 | ||||
| 29. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-89. http://dx.doi.org/10.1056/NEJMoa063070 | ||||
| 30. Malo de Molina RM, Mortensen EM, Restrepo MI, et al. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur Respir J 2010; 36:751-7. http://dx.doi.org/10.1183/09031936.00077509 | ||||
| 31. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease. A Metaanalysis. Arch Intern Med 2009; 169:219-29. http://dx.doi.org/10.1001/archinternmed.2008.550 | ||||
| 32. Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ 2013; 346:f3306. http://dx.doi.org/10.1136/bmj.f3306 | ||||
| 33. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374:685-94. http://dx.doi.org/10.1016/S0140-6736(09)61255-1 | ||||
| 34. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long-acting bronchodilators: two randomised clinical trials. Lancet 2009; 374:695-703. http://dx.doi.org/10.1016/S0140-6736(09)61252-6 | ||||
| 35. Fishman A, Martinez F, Naunheim K et al; National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume–reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059-73. http://dx.doi.org/10.1056/NEJMoa030287 | ||||
| 36. Criner GJ, Cordova F, Sternberg AL, Martinez FJ. The National Emphysema Treatment Trial (NETT) Part II: Lessons learned about lung volume reduction surgery. Am J Respir Crit Care Med 2011; 184:881-93. http://dx.doi.org/10.1164/rccm.201103-0455CI | ||||
| 37. Taneja A. Bronchoscopic interventions in the management of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2013; 19:145-51. http://dx.doi.org/10.1097/MCP.0b013e32835cfd59 | ||||
| 38. Venuta F, Anile M, Diso D, et al. Long-term follow-up after bronchoscopic lung volume reduction in patients with emphysema. Eur Respir J 2012; 39:1084-9. http://dx.doi.org/10.1183/09031936.00071311 | ||||
| 39. Herth FJ, Noppen M, Valipour A, et al; International VENT Study Group. Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort. Eur Respir J 2012; 39:1334-42. http://dx.doi.org/10.1183/09031936.00161611 | ||||
| 40. Herth FJ, Eberhardt R, Gompelmann D, et al. Radiological and clinical outcomes of using ChartisTM to plan endobronchial valve treatment. Eur Respir J 2013; 41:302-8. http://dx.doi.org/10.1183/09031936.00015312 | ||||
| 41. Nici L, ZuWallack R, American Thoracic Society Subcommittee on Integrated Care of the COPD Patient. An Official American Thoracic Society workshop report: the Integrated Care of The COPD Patient. Proc Am Thorac Soc 2012; 9:9-18. http://dx.doi.org/10.1513/pats.201201-014ST | ||||
| 42. Adams SG, Smith PK, Allan PF, et al. Systematic review of the chronic care model in chronic obstructive pulmonary disease prevention and management. Arch Intern Med 2007; 167:551-61. http://dx.doi.org/10.1001/archinte.167.6.551 | ||||